Harold Moses - Concepedia

Author

Harold Moses

Vanderbilt University Medical Center

Also Known As

HAROLD MOSES, Harold H. Moses, Harold Moses, Harold Moses Jr, Tamara Miller

Publications

1.3K

Citations

H-Index

Concepts

All Affiliations

Vanderbilt University Medical Center Vanderbilt University Northwestern University Ottawa Hospital Research Institute Merck (Germany)

About

Harold Moses is an author at Vanderbilt University Medical Center specializing in medicine, neurology, and neuropathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	718
2	Social Sciences	2	2	187
3	Health Sciences	1	1	15
4	Nursing	1	1	16
5	Public Health	1	1	16

Harold Moses

Publications

1.2K

Citations

H-Index

Page 1

	Year	Citations
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension Raju Kapoor, Pei‐Ran Ho, Nolan Campbell, The Lancet Neurology Disease ProgressionNeurological DisorderImmunologyClinical TrialsNeurology	2018	327
Infliximab for the treatment of CNS sarcoidosis Jeffrey M. Gelfand, Michael Bradshaw, Barney J. Stern, Neurology	2017	183
Diagnostic and therapeutic aspects of Hashimoto's encephalopathy Inan Olmez, Harold Moses, Subramaniam Sriram, Journal of the Neurological Sciences NeuropsychologyNeurological DisorderNeuroanatomyMedicineNeurology	2013	159
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial Bruce Cree, Gary Cutter, Jerry S. Wolinsky, The Lancet Neurology	2020	99
Influenza A virus-associated acute necrotizing encephalopathy in the United States Jörn-Hendrik Weitkamp, Michele Spring, TERRANCE BROGAN, The Pediatric Infectious Disease Journal Virus EpidemiologyNeurological DisorderNeurovirologyMedicineViral Pathogenesis	2004	72
Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis Robert J. Fox, Christopher S. Coffey, Merit Cudkowicz, Contemporary Clinical Trials Neurological DisorderClinical NeurologyClinical TrialsNeurological ProgressProgressive Multiple Sclerosis	2016	66
Cladribine tablets added to IFN-β in active relapsing MS Xavier Montalbán, Thomas Leist, Bruce A. Cohen, Neurology Neuroimmunology & Neuroinflammation	2018	60
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY) Stanley Cohan, Harold Moses, Jonathan Calkwood, Multiple Sclerosis and Related Disorders	2018	51
The spectrum of Susac’s syndrome Siddharama Pawate, Anita Agarwal, Harold Moses, Neurological Sciences MedicineProgressive Supranuclear PalsySusac ’NeuropathologyNeuromuscular Pathology	2009	35
Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis Harold Moses, David Brandes Current Medical Research and Opinion	2008	31

Page 1